Panbela announces issuance of new patent in the us and canada; patent is for claims of a fixed dose combination of eflornithine and sulindac

Minneapolis, may 06, 2024 (globe newswire) -- panbela therapeutics, inc. (otcqb: pbla), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an issue notification for the us continuation patent us 11,925,613 b2 and canadian patent ca 3003149 titled “eflornithine and sulindac, a fixed dose combination formulation”. these patents claim a novel composition of a fixed dose combination of eflornithine and sulindac, which is called flynpovi.
PBLA Ratings Summary
PBLA Quant Ranking